Lilly Trade: Buy the GLP-1 Growth Story — Hedge the Novo Nordisk Oral Threat
Eli Lilly is trading with strong momentum after robust GLP-1 sales and pipeline news, but new oral pills from competitors could create headline-driven volatility. We propose a mid-term long on LLY with a defined entry, stop and target while outlining catalysts and risks tied to competition from Novo Nordisk and others.